Homology Medicines Inc
NASDAQ:QTTB

Watchlist Manager
Homology Medicines Inc Logo
Homology Medicines Inc
NASDAQ:QTTB
Watchlist
Price: 3.03 USD 5.21% Market Closed
Market Cap: 37.3m USD

Homology Medicines Inc
Net Change in Cash

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Homology Medicines Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Homology Medicines Inc
NASDAQ:QTTB
Net Change in Cash
-$42.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Change in Cash
-$1.6B
CAGR 3-Years
-67%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Net Change in Cash
$2.3B
CAGR 3-Years
90%
CAGR 5-Years
-8%
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Net Change in Cash
$434m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Change in Cash
-$300.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Change in Cash
$501.3m
CAGR 3-Years
103%
CAGR 5-Years
22%
CAGR 10-Years
51%
No Stocks Found

Homology Medicines Inc
Glance View

Market Cap
37m USD
Industry
Biotechnology

Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. The company is headquartered in Bedford, Massachusetts and currently employs 224 full-time employees. The company went IPO on 2018-03-28. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

QTTB Intrinsic Value
3.93 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Homology Medicines Inc's Net Change in Cash?
Net Change in Cash
-49.2m USD

Based on the financial report for Mar 31, 2025, Homology Medicines Inc's Net Change in Cash amounts to -49.2m USD.

Back to Top